FDAnews
www.fdanews.com/articles/81566-data-from-exelixis-clinical-trials-to-be-presented-at-conference

DATA FROM EXELIXIS CLINICAL TRIALS TO BE PRESENTED AT CONFERENCE

October 11, 2005

Exelixis has been notified by three of its clinical investigators that abstracts containing data from the company's ongoing Phase I clinical trials of XL647, XL999 and XL880 have been accepted for presentation at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.

The abstracts are: a Phase I dose-escalation and pharmacokinetic study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies; a Phase I dose-escalation and pharmacokinetic study of a novel spectrum selective kinase inhibitor, XL999, in patients with advanced solid malignancies; and a Phase I study of a novel spectrum selective kinase inhibitor, XL880, administered orally in patients with advanced solid malignancies.